|Share Name||Share Symbol||Market||Type||Share ISIN||Share Description|
|Proteome||LSE:PRM||London||Ordinary Share||GB0003104196||ORD 1P|
|Price Change||% Change||Share Price||Bid Price||Offer Price||High Price||Low Price||Open Price||Shares Traded||Last Trade|
|Industry Sector||Turnover (m)||Profit (m)||EPS - Basic||PE Ratio||Market Cap (m)|
|Pharmaceuticals & Biotechnology||1.9||-3.3||-1.2||-||11.77|
Proteome Sciences PLC Launch of new website
Proteome Sciences PLC
19 December 2016
Proteome Sciences plc
Launch of new website
Proteome Sciences plc (AIM:PRM) (the "Company") is pleased to announce the launch of its newly designed corporate website, as anticipated in the Company's interim results statement of 14 September 2016. The website may be found at Proteome's existing web domain of www.proteomics.com.
Corporate information published pursuant to Rule 26 of the AIM Rules for Companies remains available from this website.
For further information:
Proteome Sciences plc Jeremy Haigh, Chief Executive Officer Ian Pike, Chief Scientific Tel: +44 (0)1932 865065 Officer Geoff Ellis, Chief Financial Officer finnCap Ltd (Nominated Adviser & Broker) Tel : +44 (0)20 7220 Geoff Nash/James Thompson 0500 Tony Quirke (Broking) IFC Advisory (Public Relations) Tel : +44 (0) 203 053 Tim Metcalfe/Graham Herring/Miles 8671 Nolan
About Proteome Sciences plc. (www.proteomics.com)
Proteome Sciences is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signalling pathways (SysQuant(R) , TMTcalibrator(TM) ) and for the discovery, validation and assay development of protein biomarkers. The company has its headquarters in Cobham, UK, with laboratory facilities in London, UK and in Frankfurt, Germany from where the PS Biomarker Services(TM) division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies and to academia.
Proteome Sciences has patented a number of novel protein biomarkers for diagnostic and treatment applications in important areas of human therapeutics such as cancer, stroke and Alzheimer's disease, and these are available for license.
This information is provided by RNS
The company news service from the London Stock Exchange
(END) Dow Jones Newswires
December 19, 2016 02:00 ET (07:00 GMT)
1 Year Proteome Chart
1 Month Proteome Chart